Sitagliptin vs Insulin Glargine: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Insulin Glargine (Long-acting insulin analogue) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Insulin Glargine |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Long-acting insulin analogue |
| CAS | 486460-32-6 | 160337-95-1 |
| ATC | A10BH01 | A10AE04 |
| Molecular weight | 407.31 g/mol | 6063 Da |
| Brands with this active ingredient | 1 | 1 |
What they share
Sitagliptin and Insulin Glargine share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Insulin Glargine, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: La sitagliptine inhibe de façon réversible la DPP-4, sérine protéase responsable de la dégradation rapide du glucagon-like peptide 1 (GLP-1) et du polypeptide insulinotrope glucose-dépendant (GIP). Insulin Glargine: L'insuline glargine se lie au récepteur de l'insuline avec une affinité proche de celle de l'insuline humaine, activant une signalisation intracellulaire qui augmente la captation du glucose par le muscle et le tissu adi…
Indications compared
Sitagliptin: La sitagliptine est autorisée chez l'adulte atteint de diabète de type 2, seule ou en association à d'autres antidiabétiques, pour améliorer le contrôle glycémique. Insulin Glargine: L'insuline glargine est autorisée comme insulinothérapie basale chez l'adulte et l'enfant atteints de diabète de type 1, et chez l'adulte atteint de diabète de type 2 lorsque les traitements oraux ou injectables non insu…
Safety profile
Sitagliptin: La sitagliptine est généralement bien tolérée. Insulin Glargine: L'hypoglycémie est l'effet indésirable le plus important de toute insuline et peut être sévère en cas de repas sauté, d'effort prolongé, de consommation d'alcool ou d'interaction avec d'autres hypoglycémiants.
Questions fréquentes
Is Sitagliptin better than Insulin Glargine? ▾
Sitagliptin and Insulin Glargine are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Insulin Glargine be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Insulin Glargine
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.